|
|
| Product Name: | AT-527 | | Synonyms: | AT-527;AT-527(Bemnifosbuvir);Bemnifosbuvir hemisulfate;Bemnifosbuvir hemisulfate (RG-6422;Inhibitor,antiviral,phosphoramidate,HCV,nucleotide,SARS-CoV,pangenotypic,Bemnifosbuvir hemisulfate,AT 527,AT527,guanosine,SARS coronavirus,Hepatitis C virus,inhibit;(2S)-isopropyl 2-(((((2R,3R,4R,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate sulfate;(2S)-Isopropyl 2-(((((2R,3R,4R,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate hemisulfate;Bemnifosbuvir Hemisulfate (AT-527) ，E1013 | | CAS: | 2241337-84-6 | | MF: | C24H35FN7O11PS | | MW: | 679.61 | | EINECS: | | | Product Categories: | | | Mol File: | 2241337-84-6.mol |  |
| | AT-527 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : 180 mg/mL (285.45 mM; Need ultrasonic) | | form | Solid | | color | White to off-white | | InChIKey | MKBNJIGFOVMYRL-DBENCIMWNA-N | | SMILES | S(O)(O)(=O)=O.C[C@]1([C@@H]([C@@H](COP(=O)(N[C@@H](C)C(=O)OC(C)C)OC2C=CC=CC=2)O[C@H]1N1C=NC2=C(N=C(N)N=C12)NC)O)F |&1:6,7,8,14,30,r| |
| | AT-527 Usage And Synthesis |
| Uses | Bemnifosbuvir hemisulfate (AT-527), a hemisulfate salt of AT-511, a guanosine nucleotide proagent, is a potent and orally active HCV viral replication inhibitor. Bemnifosbuvir hemisulfate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC90=0.47 μM). Bemnifosbuvir hemisulfate has pangenotypic antiviral activity[1][2][3]. | | in vivo | When given orally to rats (500 mg/kg) and monkeys (30 mg/kg, 100 mg/kg or 300 mg/kg), Bemnifosbuvir hemisulfate preferentially delivers high levels of AT-9010 in the liver in vivo[1]. | | References | [1] Steven S Good, et al. Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus. PLoS One. 2020 Jan 8;15(1):e0227104. DOI:10.1371/journal.pone.0227104
[2] Steven S Good, et al. AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19. Antimicrob Agents Chemother. 2021 Feb 8;AAC.02479-20. DOI:10.1128/AAC.02479-20
[3] Elina Berliba, et al. Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis. Antimicrob Agents Chemother. 2019 Sep 30;63(12):e01201-19. DOI:10.1128/AAC.01201-19 |
| | AT-527 Preparation Products And Raw materials |
|